Blog
RSS FeedPosted by Michael Wonder on 10 Jul 2018
Time to entry for new cancer medicines: from European Union wide marketing authorisation to patient access in Belgium, Estonia, Scotland, and Sweden
10 July 2018 - This study quantified the median time from European Union wide approval to first use for a ...
Posted by Michael Wonder on 19 Jun 2018
Vertex reaches agreement in Sweden for reimbursement of Orkambi
18 June 2018 - Vertex Pharmaceuticals announced that Orkambi (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic ...
Posted by Michael Wonder on 19 Jun 2018
Patients call for end to two-year row over cystic fibrosis drug funding
19 June 2018 - UK patients are stepping up efforts to resolve the “heartbreaking” row that is denying their families ...
Posted by Michael Wonder on 09 Dec 2016
Sweden launches campaign to host EU drugs agency instead of UK after Brexit
8 December 2016 - Britain's negotiations over leaving the EU have not even begun and already European countries are vying ...